Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enadenotucirev in locally advanced rectal cancer
NCT03916510Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jul 2019
- Primary completion
- Feb 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of enadenotucirev in rectal cancer (4 arms), sponsored by University of Oxford. Primary endpoints: Dose Limiting Toxicity at 13 weeks and Magnetic Resonance Imaging Tumour Regression Grade at 13 weeks. Started Jul 2019; status: completed.
02
Drugs
enadenotucirev
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03916510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916510.